Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul|||0000-0002-5926-8437
  • Gervais, A.
  • Taniguchi, M.
  • Saare, L.
  • Särekannu, K.
  • Voyer, T.L.
  • Philippot, Q.
  • Rosain, J.
  • Bizien, L.
  • Asano, T.
  • Garcia-Prat, Marina|||0000-0001-5387-1908
  • Parra-Martínez, Alba|||0000-0002-9564-8912
  • Migaud, M.
  • Tsumura, M.
  • Conti, F.
  • Belot, Alexandre|||0000-0003-4902-5332
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Morio, T.
  • Tanaka, J.
  • Javouhey, E.
  • Haerynck, F.
  • Duvlis, S.
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Keles, S.
  • Tandjaoui-Lambiotte, Y.
  • Escoda, S.
  • Husain, M.
  • Pan-Hammarström, Q.
  • Hammarström, L.
  • Ahlijah, G.
  • Haidar, A.A.
  • Soudee, C.
  • Arseguel, V.
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Sahanic, S.
  • Tancevski, I.
  • Nukui, Y.
  • Hayakawa, S.
  • Chrousos, G.P.
  • Michos, A.
  • Tatsi, E.B.
  • Filippatos, F.
  • Rodriguez-Palmero, A.
  • Troya, Jesús|||0000-0001-7323-114X
  • Tipu, I.
  • Meyts, I.
  • Roussel, L.
  • Ostrowski, S.R.
  • Schidlowski, L.
  • Prando, C.
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Cheikh, N.
  • Bousfiha, A.A.
  • Bakkouri, J.E.
  • Peterson, P.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Lévy, R.
  • Quartier, P.
  • Vinh, D.C.
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Béziat, V.
  • Zhang, S.Y.
  • Borghesi, A.
  • Pession, A.
  • Andreakos, E.
  • Marr, N.
  • Mentis, A.F.A.
  • H.mogensen, T.
  • Rodríguez-Gallego, C.
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Tillmann, V.
  • Neven, B.
  • Trouillet-Assant, S.
  • Brodin, P.
  • Abel, Laurent|||0000-0001-7016-6493
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Zhang, Q.
  • Martinón Torres, Federico|||0000-0002-9023-581X
  • Salas, A.
  • Gómez-Carballa, A.
  • Gonzalez-Granado, L.I.
  • Kisand, K.
  • Okada, S.
  • Puel, A.
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • AlKhater, Suzan|||0000-0001-7315-6581
  • Alkan, G.
  • Castagnoli, R.
  • Cyrus, C.|||0000-0001-7333-6486
  • Bozdemir, S.E.
  • Emiroglu, M.
  • Gulhan, Belgin|||0000-0003-0839-1301
  • Erdeniz, E.H.
  • Hatipoglu, N.
  • Bayhan, G.I.|||0000-0002-1423-4348
  • Jabandziev, P.
  • Yuksek, S.K.
  • Karbuz, A.
  • Öz, Ş.K.T.
  • Marseglia, G.L.
  • Akcan, O.M.
  • Kılıç, A.O.
  • Parlakay, A.O.
  • Papadaki, M.
  • Slaba, K.
  • Sevketoglu, Esra|||0000-0002-8330-2877
  • Valencia-Ramos, J.
  • Yahşi, A.
  • Tuala, C.
  • Urbieta, A.I.D.
  • Esteban, B.D.
  • Santalla, M.J.D.
  • Pérez, C.F.
  • Villaverde, J.F.
  • Rodríguez, C.G.
  • Allut, J.L.G.
  • Vicente, L.G.
  • Vázquez, E.G.
  • Carballa, A.G.
  • Rial, J.G.
  • Barcala, F.J.G.
  • Liñares, B.G.
  • Iglesias, P.L.
  • Massa, B.L.
  • Fuentes, M.L.
  • Franco, M.L.
  • Lago, A.L.
  • Cruz, D.N.D.l
  • Masid, E.N.
  • Devesa, J.B.O.
  • Seco, J.P.
  • Núñez, M.P.
  • Bernal, M.P.D.M.
  • Freixo, H.P.
  • Rodríguez, L.P.
  • Pischedda, S.
  • Romero, M.P.
  • Reino, A.P.
  • Hervella, G.M.P.
  • Verdes, T.Q.
  • Redondo Collazo, Lorenzo|||0000-0002-3521-678X
  • Casuso, P.R.
  • García, S.R.
  • Vázquez, S.R.
  • Blanco, V.R.
  • Calle, I.R.
  • Velasco, C.R.
  • Núñez, N.R.
  • Sánchez, C.R.T.
  • Paz, E.S.
  • Orayyou, J.M.S.
  • Villanueva, C.S.
  • Fernández, S.S.
  • Sanmartín, P.S.
  • Muñiz, M.T.
  • Pena, R.T.
  • Castellano, M.T.
  • Cuadrado, L.V.
  • García, P.V.
  • Iglesias, M.S.V.
  • Lasheras, S.V.
  • Ferreiro Iglesias, Rocío|||0000-0002-0469-4332
  • Bastón-Rey, I.
  • Calviño-Suárez, C.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Al-Muhsen, S.
  • Al-Mulla, F.
  • Amara, A.
  • Anderson, M.S.
  • Arias, A.A.
  • Arkin, L.M.
  • Feldman, H.B.
  • Biggs, C.M.
  • Bogunovic, Dusan|||0000-0002-9277-3232
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Bondarenko, A.|||0000-0002-9737-2868
  • Bryceson, Y.
  • Butte, M.J.
  • Casari, G.
  • Christodoulou, J.
  • Constantinescu, S.N.
  • Cooper, M.A.
  • Dalgard, C.L.
  • Desai, M.
  • Drolet, B.A.
  • Duval, X.
  • Baghdadi, J.E.
  • Eloy, P.
  • Espinosa-Padilla, S.
  • Fellay, Jacques|||0000-0002-8240-939X
  • Flores, Carlos|||0000-0001-5352-069X
  • Franco, J.L.
  • Froidure, A.
  • Gorochov, G.
  • Gregersen, P.K.
  • Grimbacher, B.
  • Hagin, D.
  • Halwani, R.
  • Heath, J.R.
  • Hsieh, E.W.Y.
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Imai, K.
  • Itan, Yuval
  • Jarvis, E.D.
  • Kaja, E.
  • Karamitros, T.
  • Ku, C.L.
  • Lau, Y.L.
  • Ling, Y.
  • Lucas, C.L.
  • Mansouri, D.
  • Maródi, L.
  • Mentré, F.
  • Milner, J.D.
  • Mironska, K.
  • Mogensen, T.H.
  • Ng, L.F.P.
  • Notarangelo, L.D.
  • Novelli, A.
  • Novelli, G.
  • O'Farrelly, C.
  • Okamoto, K.
  • Pape, J.W.
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Perez-Tur, J.
  • Perlin, D.S.
  • Pesole, G.
  • Planas, A.M.
  • Quintana-Murci, L.
  • Ramaswamy, S.
  • Renia, L.
  • Resnick, I.
  • Sancho-Shimizu, V.
  • Sediva, A.
  • Seppänen, M.R.J.
  • Shahrooei, M.
  • Shcherbina, A.
  • Slaby, O.
  • Snow, A.L.
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Soumelis, V.
  • Spaan, A.N.
  • Su, H.C.
  • Tangye, S.G.
  • Tayoun, A.A.
  • Temel, Ş.G.
  • Thorball, C.
  • Tiberghien, P.
  • Turvey, S.E.
  • Uddin, K.M.F.
  • Uddin, M.J.
  • Beek, D.v.d
  • Bernuth, H.v
  • Wauters, J.
  • Zatz, Mayana|||0000-0003-3970-8025
  • Zawadzki, Pawel
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-ω and/or IFN-α2.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study

  • Manzanares, Ángela
  • Pardo Seco, Jacobo José
  • Rivero Calle, Irene
  • Dacosta Urbieta, Ana Isabel
  • Mallah, Narmeen
  • Rodríguez-Tenreiro Sánchez, Carmen
  • Salas Ellacuriaga, Antonio
  • Martinón Torres, Federico
As part of the NIRSEGAL study (https://www.nirsegal.es/en), we present the clinical characteristics and course of respiratory syncytial virus (RSV)-related low respiratory tract infection (LRTI) hospitalizations in infants eligible for nirsevimab administration during the 2023–2024 season. Infants eligible for nirsevimab immunization (born between 1 April, 2023, and 30 March, 2024) who were hospitalized due to RSV-related LRTI between September 25, 2023, and April 15, 2024, in a hospital from the Galician Public Health system were included. Clinical and demographic characteristics of RSV-related LRTI hospitalizations were analyzed, with comparisons made between breakthrough cases (those immunized with nirsevimab) and non-breakthrough cases. During the study period, 69 RSV-related LRTI hospitalizations were recorded, with a median hospital stay of 4 (interquartile range (IQR) 3–6) days; 65.2% (N=45) were breakthrough cases. The median age was 2.7 (IQR 1.5–5.2) months, and more than half of them (N=39, 56.5%) were male. The incidence of cases was parallel to the RSV epidemic curve, suggesting no waning of nirsevimab efcacy. Of the total hospitalizations, 16 infants (23.2%) had a high-risk condition, 44 (63.8%) needed oxygen support, 15 (21.7%) were admitted to the intensive care unit (ICU), and 11 (15.9%) received non-invasive mechanical ventilation (NIMV). No statistically signifcant diferences were observed in these characteristics when comparing breakthrough and non-breakthrough cases. Conclusion: In the nirsevimab era, a substantial proportion of children who were hospitalized for RSV-related LRTI needed oxygen support, NIMV, and ICU admission. Clinical characteristics, timing, and outcomes were comparable between breakthrough and non-breakthrough cases. Trial registration: The NIRSE-GAL study protocol was registered on ClinicalTrials.gov (NCT06180993).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

GUANIN: an all-in-one GUi-driven analyzer for NanoString interactive normalization

  • Montoto Louzao, Julián
  • Gómez-Carballa, Alberto
  • Bello, Xabier
  • Pardo-Seco, Jacobo
  • Camino-Mera, Alba
  • Viz-Lasheras, Sandra
  • Martín, María J.
  • Martinon-Torres, Federico
  • Salas, Antonio
GUANIN can be installed with pip install GUANIN and it is available at https://pypi.org/project/guanin/. Source code, documentation, and case studies are available at https://github.com/julimontoto/guanin under the GPLv3 license., [Abstract]: Most tools for normalizing NanoString gene expression data, apart from the default NanoString nCounter software, are R packages that focus on technical normalization and lack configurable parameters. However, content normalization is the most sensitive, experiment-specific, and relevant step to preprocess NanoString data. Currently this step requires the use of multiple tools and a deep understanding of data management by the researcher. We present GUANIN, a comprehensive normalization tool that integrates both new and well-established methods, offering a wide variety of options to introduce, filter, choose, and evaluate reference genes for content normalization. GUANIN allows the introduction of genes from an endogenous subset as reference genes, addressing housekeeping-related selection problems. It performs a specific and straightforward normalization approach for each experiment, using a wide variety of parameters with suggested default values. GUANIN provides a large number of informative output files that enable the iterative refinement of the normalization process. In terms of normalization, GUANIN matches or outperforms other available methods. Importantly, it allows researchers to interact comprehensively with the data preprocessing step without programming knowledge, thanks to its easy-to-use Graphical User Interface (GUI)., The supercomputer FinisTerrae III and its permanent data storage system have been funded by the Spanish Ministry of Science and Innovation, the Galician Government, and the European Regional Development Fund (ERDF). This study also received support by (i) ISCIII: TRINEO: PI22/00162; DIAVIR: DTS19/00049; Resvi-Omics: PI19/01039 (A.S.), ReSVinext: PI16/01569, Enterogen: PI19/01090 (F.M.-T.), cofinanciados FEDER, (ii) GAIN: IN607B 2020/08 and IN607A 2023/02 (A.S.), GEN-COVID: IN845D 2020/23 (F.M.-T.), IIN607A2021/05 (F.M.-T.); (iii) ACIS: BI-BACVIR (PRIS-3, to A.S.), CovidPhy (SA 304 C, to A.S.); and (iv) consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; to A.S. and F.M.-T.). In addition, this study has been funded by ISCIII through the project “CP23/00080” and co-funded by the European Union. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Xunta de Galicia; IN607B 2020/08, Xunta de Galicia; IN607A 2023/02, Xunta de Galicia; IN845D 2020/23, Xunta de Galicia; IIN607A2021/05, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias; CB21/06/00103
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO)

  • Martinón-Torres, Federico
  • García-Sastre, Adolfo
  • Pollard, Andrew J.
  • Martín, Carlos
  • Osterhaus, Albert
  • Ladhani, Shamez N.
  • Ramilo, Octavio
  • Gómez Rial, Jose
  • Salas, Antonio
  • Bosch, F. Xavier
  • Martinón-Torres, María
  • Mina, Michael J.
  • Cherry, James
TIPiCO is an annual expert meeting and workshop on infectious diseases and vaccination. The edition of 2020 changed its name and format to aTIPiCO, the first series and podcasts on infectious diseases and vaccines. A total of 13 prestigious experts from different countries participated in this edition launched on the 26 November 2020. The state of the art of coronavirus disease-2019 (COVID-19) and the responsible pathogen, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and the options to tackle the pandemic situation were discussed in light of the knowledge in November 2020. Despite COVID-19, the status of other infectious diseases, including influenza infections, respiratory syncytial virus disease, human papillomavirus infection, measles, pertussis, tuberculosis, meningococcal disease, and pneumococcal disease, were also addressed. The essential lessons that can be learned from these diseases and their vaccines to use in the COVID-19 pandemic were also commented with the experts. © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies

  • Broset, E.
  • Pardo-Seco, J.
  • Kanno, A.I.
  • Aguilo, N.
  • Dacosta, A.I.
  • Rivero-Calle, I.
  • Gonzalo-Asensio, J.
  • Locht, C.
  • Leite, L.C.C.
  • Martin, C.
  • Martinón-Torres, F.
Background: The Bacillus Calmette-Guérin (BCG), the only vaccine against tuberculosis (TB) currently in use, has shown beneficial effects against unrelated infections and to enhance immune responses to vaccines. However, there is little evidence regarding the influence of BCG vaccination on pertussis. Methods: Here, we studied the ability of BCG to improve the immune responses to diphtheria, tetanus, and acellular (DTaP) or whole-cell pertussis (DTwP) vaccination in a mouse model. We included MTBVAC, an experimental live-attenuated vaccine derived from Mycobacterium tuberculosis, in our studies to explore if it presents similar heterologous immunity as BCG. Furthermore, we explored the potential effect of routine BCG vaccination on pertussis incidence worldwide. Findings: We found that both BCG and MTBVAC when administered before DTaP, triggered Th1 immune responses against diphtheria, tetanus, and pertussis in mice. Immunization with DTaP alone failed to trigger a Th1 response, as measured by the production of IFN-¿. Humoral responses against DTaP antigens were also enhanced by previous immunization with BCG or MTBVAC. Furthermore, exploration of human epidemiological data showed that pertussis incidence was 10-fold lower in countries that use DTaP and BCG compared to countries that use only DTaP. Interpretation: BCG vaccination may have a beneficial impact on the protection against pertussis conferred by DTaP. Further randomized controlled trials are needed to properly define the impact of BCG on pertussis incidence in a controlled setting. This could be a major finding that would support changes in immunization policies.